Použitá literatúra

  1. Ambati J, et al. Age-related macular degeneration: etiology, pathogenesis and therapeutic strategies. Survey of Ophthalmology2001; 48(3) 257-293
  2. Klein R et al. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1992 Jun; 99(6): 933-43
  3. Kahn HA et al. The Framingham Eye Study I: Outline and major prevalence findings, Am J Epidem. 1977; Jul: 106(1): 17-32
  4. Vingerling JR et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology. 1995 Feb; 102(2): 205-10
  5. Mitchell P et al. Prevalence of age-related maculopathy in Australia: The Blue Mountains Eye Study. Ophthalmology. 1995; Oct; 102(10): 1450-60
  6. Freidman DS et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthal 2004; 122(4): 564-72
  7. Thylefors B, et al. Global data on blindness. Bull WHO. 1995; 73: 115-121.
  8. Ferris FL, Kassoff A, Bresnick GH, et al (1982). New visual acuity charts for clinical research. Am J Ophthalmol; 94:91–96
  9. Macula Photocoalgulation Study Group (1991). Laser photocoalgulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial, Arch Ophthalmol; 109(9):1220-31
  10. Rosenfeld PJ, Martidis A, Tennant MTS. Age-relatedmacular degeneration. In: Ophthalmology. 3rd edn. YanoffM, Duker JS (editors). Philadelphia: Mosby/Elsevier; 2009:pp. 658–673
  11. Brown MM, Brown GC, Stein JDet al.Age-related maculardegeneration: economic burden and value-based medicineanalysis. Can J Ophthalmol2005;40:277–287.
  12. Williams RA, Brody BL, Thomas RG, Kaplan RM, BrownSI. The psychosocial impact of macular degeneration. ArchOphthalmol1998;116:514–52
  13. Young RW(1987). Pathophysiology of age-related macular degeneration. Surv.Ophthalmol; 31:291-30
  14. Gree WR (1999). Histopathology of age-related macular degeneration. Mol Vis; 5:27
  15. Matice E & Wolfe CP (1986)Using the Amsler grid. J Ophthalmic Nurs Technol; 5(1):34
  16. Bird AC Bressler NM, Bressler SB, et all (1995) An international classification and granding system for age-related maculopathy and age-related macular degeneration.The International ARM Epidemiological study group. Surv.Ophthalmol; 39:367-74
  17. McGraw P, Winn B, Whitaker D. Reliability of the Snellen chart. BMJ.1995; 310(6993):1481-1482
  18. Yang CS, Cheng CY, Lee FL, et al (2001). Quantitative assessment of retinal thickness in diabetic patients with and without clinically significant macular edema using optical coherence tomography. Actual Ophthalmol Scand; 79(3):266-70
  19. Bressler NM (2002). Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract; 15(2):142-52
  20. Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 2010;10:31
  21. Hirakawa M, Tanaka M, Tanaka Y, Okubo A, Koriyama C, Tsuji M et al. Age-related maculopathy and sunlight exposure evaluated by objective measurement. Br J Ophthalmol 2008;92(5):630-634
  22. Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye (Lond) 2005;19(9):935-944
  23. Smith W, Mitchell P, Leeder SR. Smoking and age-related maculopathy. The Blue Mountains Eye Study. Arch Ophthalmol 1996;114(12):1518-1523
  24. Mares JA, Moeller SM. Diet and age-related macular degeneration: expanding our view. Am J Clin Nutr 2006;83(4):733-734
  25. www.health.gov.sk